-
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B
The purpose of the study is to evaluate the safety, tolerability and efficacy of 1 or more experimental arms for the treatment of advanced renal ... -
Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET gene abnormalities
The purpose of the study is to determine the safety and tolerability of TAS0953/HM06. We want to know what is the best study drug ... -
A PHASE 1/2 OPEN-LABEL DOSE-ESCALATION SAFETY AND TOLERABILITY STUDY OF NC410 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
The purpose of the study is to determine the safety and tolerability of NC410, and to assess the preliminary efficacy of NC410 in subjects with ... -
A Phase 1/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma ( s21-00991)
The purpose of the study is to determine the side effects and best dose of M3814. We want to see how well the drug M3814 ... -
A Phase 1/2 Dose Escalation And Dose Expansion Study Of BA3021 Alone And In Combination With Nivolumab In Patients With Advanced Solid Tumors
The purpose of the study is to determine and evaluate the safety, tolerability, immunogenicity, and antitumor activity of BA3021 alone and in combination with nivolumab ... -
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC
The purpose of the study is to evaluate the safety and efficacy of intravesical administration of EG-70 and its effect on bladder tumors in patients ... -
A Phase 1/2a Multi-Center Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of JAB-3312 in combination with pembrolizumab or binimetinib in Adult Patients with Advanced Solid Tumors
The purpose of the study is to determine and demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 or MEKi in patients with ... -
Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C
The purpose of the study is to determine and to evaluate the safety as well as efficacy of investigational treatment arms with or without pembrolizumab ... -
PHASE 1/2A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
The purpose of the study is to investigate the safety, tolerability of study drug PF-07104091, a CDK2 inhibitor, when administered as a single agent and ...
-
A Phase 1b/2 Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer.
You can participate in this study if you are diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. The ...